GSK’s Penmenvy Meningococcal Vaccine Approved by FDA
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration for use in individuals aged 10 through 25 years.
RSV Vaccine Prompts Robust Response in Older Recipients
Findings of a Phase III randomized controlled trial showed Pfizer’s RSV Prefusion F (RSVpreF) vaccine triggered strong immune responses among people aged 60 years and older during its first two seasons.
Grant Awarded to Accelerate Pandemic Influenza mRNA Vaccine Development
The U.S. Department of Health andHuman Services will provide approximately $590 million to Moderna to accelerate the development of mRNAbased pandemic influenza vaccines and enhance mRNA platform capabilities
New Personalized Vaccine May Treat Pancreatic Cancer
A new study published in the journal Nature found that a personalized vaccine, named autogene cevumeran, is showing promising results for treating pancreatic cancer, one of the deadliest malignancies.
Vaccine Shows Promise In Stopping Plaque Buildup in Arteries
Chinese researchers have developed a “cocktail” nanovaccine to prevent plaque from building up in the arteries, an underlying factor in heart disease, which is the leading cause of death worldwide.
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA
GSK’s Penmenvy (meningococcal groups A, B, C, W and Y vaccine) has been approved by the U.S. Food and Drug Administration (FDA) for use in individuals aged 10 through 25 years.
HIV Vaccine Elicits Potent Response in Nonhuman Primates
A study conducted by researchers at Weill Cornell Medicine has demonstrated that a series of six vaccinations containing a modified protein from the surface of HIV particles stimulated initial steps of a potent immune response in young nonhuman primates.
First Nasal Self-Administered Flu Vaccine Approved by FDA
FluMist, the first influenza nasal spray vaccine that can be self-administered, has been approved by the U.S. Food and Drug Administration (FDA).
Study Finds Flu Vaccine Over 50% Effective Against Severe Disease in Children
According to a recent study published in JAMA Network Open, the estimated effectiveness of at least one dose of the influenza vaccine against emergency department visits or hospitalization was over 50 percent across disease severity levels among nearly 16,000 U.S. children during five respiratory illness seasons.
COVID-19 Vaccine May Reduce Risk of Developing Long COVID
A new study published in the journal Vaccine, shows that receiving a COVID-19 vaccine could reduce the risk of developing long COVID if it’s administered five months before an infection.